178.25MMarket Cap-0.77P/E (TTM)
0.625High0.588Low1.76MVolume0.605Open0.582Pre Close1.07MTurnover0.81%Turnover RatioLossP/E (Static)292.16MShares3.25652wk High0.34P/B132.11MFloat Cap0.50952wk Low--Dividend TTM216.54MShs Float19.840Historical High--Div YieldTTM6.34%Amplitude0.509Historical Low0.609Avg Price1Lot Size
Lyell Immunopharma Stock Forum
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...
Dow Jones· just
$Lyell Immunopharma (LYEL.US)$
No comment yet